Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
about
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killingCrystal Structures of the Glycopeptide Sulfotransferase Teg12 in a Complex with the Teicoplanin AglyconeThe 2.7 Å resolution structure of the glycopeptide sulfotransferase Teg14Regioselective deacetylation based on teicoplanin-complexed Orf2* crystal structuresInterception of teicoplanin oxidation intermediates yields new antimicrobial scaffoldsSystematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Update on the emerging role of telavancin in hospital-acquired infectionsManagement of multidrug-resistant enterococcal infectionsAn antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosisNewer antibacterial drugs for a new century.Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.Newly Isolated Paenibacillus tyrfis sp. nov., from Malaysian Tropical Peat Swamp Soil with Broad Spectrum Antimicrobial Activity.N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.Cloning and characterization of new glycopeptide gene clusters found in an environmental DNA megalibraryAntifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.5-Hydroxyethyl-3-tetradecanoyltetramic acid represents a novel treatment for intravascular catheter infections due to Staphylococcus aureusPharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.Postgenomic strategies in antibacterial drug discovery.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensIn vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolatesEfficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid contentTelavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyVancomycin: ligand recognition, dimerization and super-complex formation.Telavancin: a new lipoglycopeptide with multiple mechanisms of action.Role of telavancin in treatment of skin and skin structure infectionsSyntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.Macrocyclic drugs and synthetic methodologies toward macrocyclesCurrent and novel antibiotics against resistant Gram-positive bacteriaCurrent strategies for the prevention and management of central line-associated bloodstream infections.Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infectionsStructure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptidePharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.
P2860
Q24606291-30B008C4-0C61-4D61-9F58-DC820C02D7D7Q27660400-52CAA5AC-482D-4931-932C-D4F8E9BB1066Q27666133-CBD2C5C7-D613-4A29-992C-1876B5532278Q27666579-DB8E8C07-6812-4A7F-B1BE-A8BA280E3003Q27667190-E401C90D-B3C3-441A-88D8-72D16D86B779Q28078557-C904853A-12F5-4AC6-AF78-AE22FBDEFCB9Q28083522-91D694F6-C0CF-42DE-B2E9-B3542B83BEE6Q28285907-F5C6F352-A797-45A7-9DA8-5CA6B02BC5C2Q28534020-7C0717C7-94A0-464A-AEAC-5F15F84933A6Q30433333-2CDE21B3-721A-470B-BE07-AB4EE57914A3Q30727582-FE2FCF83-E789-4AFB-BF7E-89D25245A195Q31057909-2870EE83-641D-4C3E-9536-5A30A65A09FDQ31096170-600469C9-6881-4540-81F0-321E0913B782Q33382969-67D99BAA-ACBA-4A9D-86B2-3040DD795EDFQ33559043-E81E03FB-E30B-4539-8D79-E91E375BB80CQ33589815-577A9C8C-A891-4250-97BA-DE2338A6055FQ33657212-D7A486CC-3DE6-4B41-9669-7ADFE8AF8BC6Q33723124-F0DB39D6-26B6-4733-9ECA-E7EC4FCA80F8Q33745572-CA0F8F4F-0891-4B1A-B6EF-2A9EA16B7B87Q33788308-9C3E6CD2-902E-4EEA-9B05-48C037A73EC5Q33876626-144FFB58-AC36-4399-B4B6-68C8B8F60632Q34077052-4973CA35-B57C-4D28-B81F-C78999E59269Q34282738-D30E667B-8D20-4305-9CBE-D2216E80EB4CQ34390763-D853419A-F4A2-41C9-A1B9-A7D5060018F2Q34405922-656C3AB5-BB9E-4B44-A8D7-D8D12670882DQ34509652-5461E6F3-0FB0-483F-8457-AAFDE4223883Q34539275-FBA763ED-3434-4D3E-990D-73821002EB70Q34572923-7887BD4F-81E9-41E2-A90D-2ED81B61BD16Q34620329-B0DC167E-7DCF-4C5B-B706-938F726E00C6Q34645907-503A2ED8-182B-4DC4-B7CD-4E7DFF9DD40EQ34677611-5AB60B2C-194E-4CC8-85B5-F9A4116ED431Q34699108-08143264-3EE5-43E1-9DDD-99CF8B088EE2Q34737510-7EB5BC38-08EE-4B04-B768-BD2FB6E4C681Q34740721-21F642CC-0566-4208-8B00-BE6750F1E975Q35026521-2FF31937-F1A8-4621-AB55-1DFE4389B697Q35026591-FA030360-5F06-432A-B67A-F470FBB00B3CQ35026607-6357A67E-4C84-4D0B-9504-3C1FB8DE1EC2Q35190498-F9CB8A80-3785-4D8A-9E60-60F164D12486Q35224649-1CBC0EC5-445E-4244-82DE-D1D653040E99Q35603288-9EED3278-C415-44F4-8AE2-F0D828F6F75B
P2860
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@ast
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@en
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@nl
type
label
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@ast
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@en
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@nl
prefLabel
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@ast
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@en
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@nl
P2093
P2860
P3181
P1476
Telavancin, a multifunctional ...... esistant Staphylococcus aureus
@en
P2093
Bret M Benton
Dane E Karr
Deborah L Higgins
Dmitri V Debabov
Donald E Schmidt
Erik Sandvik
Joey Leung
Kevin M Krause
Koné Kaniga
Patrick P Humphrey
P2860
P304
P3181
P356
10.1128/AAC.49.3.1127-1134.2005
P407
P577
2005-03-01T00:00:00Z